Twin-to-twin transfusion syndrome (TPTS) is a prenatal condition in which one twin (the donor) loses some of its cells or plasma to the other twin (the recipient) during pregnancy. This can lead to a variety of pathological conditions in the recipient, including anemia, heart failure, and other organ dysfunction. TPTS is most often seen in monochorionic twins, who share a placenta. The condition is caused by an uneven distribution of blood vessels between the twins, which can lead to potentially life-threatening abnormalities. An important aspect of TPTS research is that clinical manifestations can vary greatly depending on the part of the body affected and the timing of the syndrome.
History of the disease and interesting historical facts
Blood transfusion syndrome was first described in medical literature in the first decade of the 20th century, but a full understanding of these complications came only later. Research on this topic has been actively developing since the 1970s, when ultrasound technologies became more accessible and developed. One of the first descriptions of the syndrome in the scientific literature was a case in which doctors discovered a difference in hemoglobin between twins during prenatal care. Further discoveries led to an understanding of the mechanism by which blood or cells are exchanged. An important fact is that among the many prenatal syndromes, TPTS has become one of the most studied in pediatrics, as it has a serious impact on the prognosis of survival of newborns.
Epidemiology
The epidemiology of twin-to-twin transfusion syndrome indicates that the disorder occurs in approximately 10-15% monochorionic twins. It is most commonly diagnosed in twins born before 34 weeks of gestation. Existing studies show that the average incidence of TPTS in monochorionic twins ranges from 15% to 30%, depending on the diagnostic methods and follow-up. It has also been found that the risk increases significantly in the presence of pregnancy complications such as preeclampsia or multiple pregnancies.
Genetic predisposition to this disease
Research suggests that genetic factors, both immune and vascular, play a role in twin-to-twin transfusion syndrome. Although TPTS is considered a rare condition, certain mutations in vasculature-related genes have been identified that may contribute to increased risk. For example, mutations in genes responsible for collagen synthesis may lead to structural weakness in the vessel walls, increasing the likelihood of cells being released into the recipient’s bloodstream.
Risk factors for the development of this disease
There are several risk factors that can significantly increase the likelihood of developing twin-to-twin transfusion syndrome, including:
- Maternal age: Women over 35 have a higher risk of complications.
- Multiple pregnancies: Excessive expansion of the placental system increases the chances of TPTS.
- Placental disorders: such as placenta previa or placenta abruption.
- Diabetes and hypertension: predispose to vascular and metabolic problems.
- Genetic factors: having a history of relatives with this condition.
Diagnosis of this disease
Twin-to-twin transfusion syndrome is diagnosed using a number of methods, including:
- The main symptoms include: anemia, hydrops fetalis, myocardial dysfunction.
- Laboratory tests: hemoglobin and hematocrit levels, tests for the presence of immunoglobulins.
- Radiological examinations: ultrasound examination to assess the volume of fluid in the twins' body cavities and the state of the cardiovascular system.
- Other types of diagnostics: magnetic resonance imaging for detailed analysis of the condition of organs.
- Differential diagnosis: It is necessary to exclude other causes of anemia, such as preeclampsia and anemia of other origin.
Treatment
Treatment of twin-to-twin transfusion syndrome requires a multidisciplinary approach, including:
- General treatment: monitoring of the condition of both twins and use of antianemic drugs are necessary.
- Pharmacological treatment: may include the use of erythropoietin to improve the recipient's hemoglobin levels.
- Surgical treatment: A blood transplant may be required in the recipient in severe cases.
- Other treatments: Serial amniocentesis to relieve hydrops.
List of medications used to treat this disease
Among the main groups of drugs used to treat twin-to-twin transfusion syndrome are:
- Erythropoietin alpha - to stimulate the production of red blood cells.
- Blood substitutes and drugs for infusion therapy.
- Corticosteroids - as anti-inflammatory agents when needed.
- Antihypertensive drugs - if there is concomitant hypertension.
Disease monitoring
Monitoring the condition of twins with transfusion syndrome is critical, periodic monitoring includes:
- Control stages: regular ultrasound examinations every 1-2 weeks during pregnancy.
- Prognosis: Depending on the detection of the syndrome and their condition, the prognosis can range from good to grave.
- Occasional complications: risk of serious complications such as heart failure or neurological damage in the recipient.
Age-related features of the disease
Twin-to-twin transfusion syndrome can manifest itself in different ways depending on age, in particular:
- In the neonatal period: twins are at greater risk of anemia and hypoxic conditions.
- In childhood: effects on growth and development may be observed if the syndrome is not adequately treated.
- In adults: the syndrome may not manifest clinically, but the possibility of neurological or vascular diseases is significantly increased.
Questions and Answers
- What is twin-to-twin transfusion syndrome? It is a prenatal condition in which one twin loses blood or plasma to the other, which can cause a number of complications in the recipient.
- What are the main symptoms of TPTS? Major symptoms include anemia, hydrops fetalis, and cardiovascular disturbances.
- What is the epidemiology of the syndrome? The syndrome occurs in approximately 10-15% monochorionic twins and is more common in those born before 34 weeks of gestation.
- How is this condition treated? Treatment includes drug therapy, possible surgery and monitoring of the twins' condition.
- What are the risks for twins with TPTS? Risks may include respiratory failure, heart problems and neurological impairment in the future.
